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No association between acetylation phenotype and alcoholism was 
discovered. Fifty-four percent of both the alcoholic patients and 
healthy volunteers were rapid acetylators. Acetylation phenotyping 
is not helpful to the investigation 01 the genetics of alcoholism. 
HERE HAS BEEN an accumulation of data suggesting T that vulnerability to alcoholism is markedly influenced 
by genetic factors. Strongest evidence for this has come 
from studies in which a higher level of concordance for 
alcoholism was found among identical than fraternal 
twins,'.' and studies of adopted offspring of alcoholics.'-' 
The identification of a genetic marker for alcoholism 
would narrow the search for a "vulnerability gene." Several 
blood proteins have been reported to differ in alcoholics 
when compared to controls,' and platelet MA0 and aden- 
ylate cyclase activity have been noted to be low in alco- 
holics.x-"' However, it is unclear whether or not these 
apparent changes predate the development of alcoholism. 
A biological marker that correlates with a genetic vulner- 
ability towards alcoholism has not been identified. One 
approach is to compare the occurrence of alcoholism to 
the expression of a readily identifiable phenotype that is 
known to be the result of two alleles at a autosomal gene 
locus, as is the acetylation phenotype."." 
Other reasons for determination of any cosegregation of 
alcoholism with the rapid or slow acetylation phenotype 
have to do with a reported increase in acetylation clearance 
of drugs when administered with alcohol".'3 and the 
metabolism of serotonin by N-acetyltransferase. Serotonin 
has been hypothesised to exhibit abnormal metabolism in 
patients with alcoholism.'" It has been reported that the 
cerebrospinal fluid concentrations of the serotonin metab- 
olite, 5-hydroxyindole acetic acid, are low in subjects who 
display pathological impulsive b e h a ~ i o r . ' ~ - ' ~  Also, person- 
ality traits associated with impulsive behavior have been 
ascribed to Type 2 alcoholics, who exhibit a strong family 
history of paternal alcoholism.'" 
METHODS 
Acetylation phenotype was established in 63 subjects: 37 abstinent 
alcoholics and 26 control subjects. All subjects were Caucasian, 18 years 
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of age or older and unrelated to any other volunteer. None exhibited any 
abnormalities on physical screening, which included a history and phys, 
ical examination, complete blood count with differential, platelet count, 
liver enzymes, albumin, BUN. creatinine, and urinalysis. Although liver 
biopsy was not performed, any alcoholic subject with abnormal liver 
enzyme values was excluded. Volunteers and alcoholic subjects were 
drug-free, with the exception of two controls; one taking conjugated 
estrogens and the other atenolol. All subjects with a history of allergy to 
sulfa drugs or glucose-6-phosphate dehydrogenase deficiency were ex- 
cluded. Acoholic patients were diagnosed as alcohol dependent according 
to DSM-111" criteria based on a structured interview using the Schedule 
for Affective Disorders and Schizophrenia-Lifetime Version."' Control 
subjects were screened with these same instruments and were admitted 
into the study only if they were free of any drinking problems and had 
no alcoholic first degree relative. All abstinent alcoholics and some 
controls stayed on an inpatient ward located at the National Institute of 
Health Clinical Center in Bethesda. MD. The alcoholic subjects had all 
been abstinent for at least 1 month prior to participation in the study. 
The remainder of the control subjects participated in the study as 
outpatients. All controls were asked to abstain from drinking any alco- 
holic beverage for 48 hr prior to the acetylator phenotype testing. 
Compliance was tested with a breath alcohol test which was required to 
be negative prior to beginning the acetylation phenotyping procedure. 
All subjects signed an informed consent form prior to participating in 
the study and control subjects were financially reimbursed. 
There were 26 controls and 37 abstinent alcoholics. There was no 
significant difference in age between the two groups (controls: 49 k I5 
years vs. alcoholics: 46 * 20 years). There was a higher proportion of 
women in the control group ( I  1 of 26 vs. 4 of 37). 
All subjects fasted from midnight on the day of the study, except for 
water, and received a 20-mg/kg oral dose of sodium sulfamethazine 
solution in the morning between 6:45 and 8 a.m. The subjects then 
continued fasting, with the exception of water. for an additional 3 hr. 
Ten milliliters of blood were drawn from an antecubital vein into a 
vacutainer tube at 5 hr following sulfamethazine administration. 
Sulfamethazine serum samples were assayed using high-performance 
liquid chromatography with UV detection employing the method of 
Whelpton et al." The concentrations of both sulfamethazine (SMZ) and 
acetylsulfamethazine (ACSMZ) were determined directly by this method. 
The percentage acetylated at 5 hr was calculated as follows (concentra- 
tions are expressed as mcg/ml)": 
'ACSMZ1 
[ACSMZ] + [SMZ] x 100 = % of total concentration acetylated 
RESULTS 
The proportions in the two groups were compared using 
a x2 test. They did not differ from each other. The per- 
centage acetylated at 5 hr showed a bimodal distribution 
in both groups (Figs. 1 and 2). The cut-off point between 
fast and slow acetylators was set at 60%. a posteriori. The 
alcoholic and control groups contained, respectively, 54% 
(20/37) and 54% (14/26) fast acetylators. Eleven of the 
male alcoholic patients had a family history of alcoholism 
based on two first degree male relatives (father and either 
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Fig. 1. The percentage of plasma sulfamethazine acetylated at 5 hr following 
oral administration to 26 control subjects. 
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Fig. 2. The percentage of plasma sulfamethazine acetylated at 5 hr following 
oral administration to 37 abstinent alcoholics. 
paternal grandfather, brother or son). Six of them were 
rapid and five were slow acetylators of sulfamethazine, 
which is no different from the proportion in the control 
subjects. 
No side-effects to the sulfamethazine were noted, with 
the exception of one complaint of a headache. 
DISCUSSION 
Our study revealed no difference in the proportions of 
slow or fast acetylators in abstinent alcoholics when com- 
pared to normal volunteers. 
Acetylator phenotype is genetically determined by two 
autosomal alleles and governs the metabolic rates of many 
drugs undergoing acetylation. Although three genotypes 
(fast, moderate, slow) exist for acetylation,’3 most com- 
monly used techniques for determining acetylation phe- 
notype only discriminate between “fast” and “slow” ace- 
tylators. Intermediate acetylators are included with fast 
acetylators when abbreviated tests, such as the one used 
in this study, are used. Acetylation rate may have a strong 
bearing on drug efficacy and also upon the presence of 
certain side-effects, especially when an acetylation step is 
the major activating or deactivating step in the metabolic 
pathway, e.g., isoniazid and hydralazine. Additionally, the 
slow acetylators show a greater incidence of arylamine- 
induced bladder cancer, since they detoxify arylamines 
more slowly than fast a~etylators.’~.” Two studies’“’’ have 
also found an association between acetylator phenotype 
and personality traits. These personality traits (neuroti- 
cism and hypochondriasis) cannot be simply related to 
those ascribed to Type 1 and Type 2 alcoholics as described 
by C10ninger.I~ 
ace- 
tylation phenotype appeared to be uninfluenced by either 
age or gender. However, recent studies report that both 
gender and age affect isoniazid acetylation rate.”.3n Gach- 
alyi et a1.3’ have also reported that age affects acetylator 
phenotype when it is determined using sulfamethazine. 
There was no significant difference in age between our 
two groups. Since gender has not been shown to be a 
significant source of variability when sulfamethazine is 
used as a phenotyping agent the greater number of females 
in our control group most likely had no effect on the 
results. 
Our phenotype results (54% fast, and 46% slow in each 
group) are in general agreement to those reported for the 
Caucasian population, 52% fast and 48% slow.3’ A power 
analysis based on our current results reveals that, should 
there be a significant difference (a = 0.05, Z,, = 1.96) 
between the two groups, a sample size of 2430 subjects 
would be required in each group to demonstrate this 
difference with a power of 80% (1 - B = 0.8, Z! = 0.84). 
Based upon this information a significant association be- 
tween acetylation phenotype and the presence of alcohol 
abuse or dependence is very unlikely. 
In the initial acetylation phenotyping 
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